Showing 1–15 of 15 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Tari Nur Fauziyantini, Umi Yuniarni, Lanny Mulqie
…especially in the case of Multidrug-Resistant Tuberculosis (MDR-TB). This study aims to examine the TB-RO therapy regimen that applies in Indonesia through a descriptive analysis approach. The research process was carried out by searching, selecting and analyzing scientific liter…
Rivaldo Heru Setiawan
…lobal public health challenge, with multidrug-resistant TB (MDR-TB) contributing substantially to poor outcomes. Conventional regimens span 18–24 months, leading to limited adherence and treatment success. Shorter treatment regimens (STRs), such as the BPaL regimen (bedaquiline, …
Serisha Ramasir, Frasia Oosthuizen, Varsha Bangalee
… of said guidelines. The multi-drug resistant tuberculosis (MDR-TB) guideline has undergone major changes over the past 5 years. These changes included shorter treatment regimens and the introduction of novel drugs. These changes have consequently impacted the management of MDR-T…
Singh S, Gumbo T, Alffenaar JW, Boorgula GD, Shankar P, et al.
…nd other drugs was tested to identify alternative treatment regimens for multidrug-resistant tuberculosis (MDR-TB). Methods The following were performed: (1) MIC experiments; (2) static time-kill studies (STKs) with different BLIs; and (3) a hollow fibre model system of TB (HFS-T…
Christian Tague
HIV coinfection and multidrug-resistant tuberculosis (MDR-TB) pose a major public health challenge in sub-Saharan Africa, where high HIV prevalence promotes tuberculosis progression and complicates its management. In people living with HIV (PLHIV), profound immunosuppression lead…
Mota F, Ruiz-Bedoya C, Tucker E, De Jesus P, Flavahan K, et al.
…anid is used in combination with bedaquiline and linezolid (BPaL regimen) in the treatment of multidrug-resistant tuberculosis (MDR-TB). However, the penetration of pretomanid in privileged sites remain unknown. Antimicrobial pharmacokinetic (PK) parameters are traditionally deri…
Carlos Acuña-Villaorduña, Karen R. Jacobson, C. Robert Horsburgh, Martin Canning, Pranay Sinha
Initial experience with BPaL-based regimens to treat multidrug-resistant TB Dear Editor, We read with interest the recent article on the latest WHO guidelines on drug-resistant TB. 1 The recommendation to implement all-oral regimens containing bedaquiline, pretomanid and linezoli…
Filipa Mota, Camilo A. Ruiz-Bedoya, Elizabeth W. Tucker, Patricia De Jesus, Kelly Flavahan, et al.
…anid is used in combination with bedaquiline and linezolid (BPaL regimen) in the treatment of multidrug-resistant tuberculosis (MDR-TB). However, the penetration of pretomanid in privileged sites remain unknown. Antimicrobial pharmacokinetic (PK) parameters are traditionally deri…
Marco Schiuma, Souleymane Hassane Harouna
Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge to global public health. Globally, the World Health Organization (WHO) estimates the number at 400,000 patients with MDR-TB for 2023. Only 44% were diagnosed and put on treatment, the therapeutic success rat…
Suman Saurabh, Pankaj Bhardwaj
… the recommendation of a shorter all-oral bedaquiline-based regimen for 9–12 months for multidrug or rifampicin-resistant (MDR/RR) tuberculosis, which replaces the current shorter regimen with injectables. The need for a shorter all-oral regimen had been long-felt by experts.[2] …
Michael Ladna
… anastomosis. Case Description/Methods: A man in his 40s on BPAL-M regimen for MDR pulmonary TB presented to Emergency Department with abdominal pain, vomiting, and cessation of bowel movements. Computed tomography abdomen/pelvis showed small bowel obstruction with a terminal ile…
Asan Medical Center
…objective of this study is to analyze the efficacy of a new regimen using Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin for 24 weeks or Bedaquiline, Pretomanid, Linezolid for 26 weeks for the treatment of MDR/RR-TB through the clinical trial. The BPaL (Bedaquiline, Pretom…
Jaya Ranjalkar, Premila M Wilfred, R. Lalitha Priya
…tuberculous drug-induced liver injury (ATDILI) for the HRZE regimen was 12.6% (95% CI, 9.9–15.3%, p < 0.001, I2 = 95.1%).4 The median onset time for HRZE associated ATDILI was 3 weeks4 (in 80% of the studies), versus 20 days.1 However, in contrast to this study,1 in India,4 a maj…
… two new recommendations, one on the composition of shorter regimens and one on the use of the BPaL regimen (i.e. bedaquiline, pretomanid and linezolid). In addition, the consolidated guidelines include existing recommendations on treatment regimens for isoniazid-resistant TB and…
… two new recommendations, one on the composition of shorter regimens and one on the use of the BPaL regimen (i.e. bedaquiline, pretomanid and linezolid). In addition, the consolidated guidelines include existing recommendations on treatment regimens for isoniazid-resistant TB and…